These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 16979988)

  • 1. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D; Kotnik V; Kandus A
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
    Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
    Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
    Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
    Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience.
    Kandus A; Grego K; Arnol M; Kovac D; Lindic J; Buturović J; Ponikvar R; Bren AF
    Transplant Proc; 2006 Nov; 38(9):2853-5. PubMed ID: 17112847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
    Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
    Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
    Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basiliximab and heart transplantation in Hispanics: the experience in Puerto Rico.
    Banchs HL; Carro Jiménez EJ; González V; González Cancel IF; Quintana C; Calderón R; Altieri PI; Rivera C
    Bol Asoc Med P R; 2007; 99(3):191-6. PubMed ID: 19610574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.